Biomedical Translational Research (eBook)

The second volume of the Biomedical translational research discusses advancements in biomedical research for understanding the pathophysiology of various diseases towards improving diagnosis and treatment. It presents the integration of molecular-based technologies, clinical genomics, and medical informatics to improve diagnostic and treatment strategies. Further, the book reviews molecular genomics approaches for diagnosis and managing tuberculosis. It also covers the innovative strategies for cancer treatment through targeting metabolic pathways, tumor microenvironment, cancer stem cells, and immune cells.  It also illuminates novel strategies for heart failure diagnosis and therapeutic approaches for the treatment of heart failure. It discusses improvements in translational research for discovery of new diagnostic tests, identifying novel biomarkers and drugable targets, and predicting optimal treatments based on understanding the underlying molecular basis of the disease. Lastly, it reviews the preclinical models of restenosis and their application and limitation in the evaluation of device-based interventional technologies for the treatment of coronary artery diseases.

Professor Ranbir Chander Sobti is an Emeritus Professor and Indian National Science Academy (INSA) senior scientist at Punjab University. He is a former Vice-Chancellor of the Panjab University, Chandigarh & Babasaheb Bhimrao Ambedkar University (Central University), Lucknow. He started his career as a cytogeneticist and then moved on to molecular biology, including genomics, to understand the susceptibility and disease process of cancer, COPD, AIDS metabolic syndrome, and kidney diseases. He has also used stem cells and nanoparticles to understand the process of tissue organ development through a designed de-cellularization protocol.  He has published more than 300 research articles in the journals of international repute and has also published more than 40 books.

He is a Fellow of the Third World Academy of Sciences, National Academy of Sciences India, Indian National Science Academy, National Academy of Medical Sciences, National Academy of Agricultural Sciences, Canadian Academy of Cardiovascular Diseases and few others. He was the General President of the Indian Science Congress for the 102nd session held at the University of Jammu in 2013. Dr. Sobti is the recipient of many prestigious awards like the INSA Young Scientist Medal, UGC Career Award, Punjab Rattan Award, JC Bose Oration and Sriram Oration Awards and of Life Time Achievement Awards of the Punjab Academy of Sciences, Zoological Society of India, and the Environment Academy of India.

Dr Awtar Krishan Ganju had been Scientific Director of Comprehensive Cancer, University of Miami Medical School. Now is Emeritus Professor, Department of Pathology in the University of Miami, Medical School, Miami. He is a renowned cancer biologist and has been one of the pioneer in the flow cytometry, cancer diagnosis and drug development. He has published a large number of papers in the international journals of repute. He is widely travelled and has trained faculty and students in flow cytometry technology world over. 

---

The second volume of the Biomedical translational research discusses advancements in biomedical research for understanding the pathophysiology of various diseases towards improving diagnosis and treatment. It presents the integration of molecular-based technologies, clinical genomics, and medical informatics to improve diagnostic and treatment strategies. Further, the book reviews molecular genomics approaches for diagnosis and managing tuberculosis. It also covers the innovative strategies for cancer treatment through targeting metabolic pathways, tumor microenvironment, cancer stem cells, and immune cells.  It also illuminates novel strategies for heart failure diagnosis and therapeutic approaches for the treatment of heart failure. It discusses improvements in translational research for discovery of new diagnostic tests, identifying novel biomarkers and drugable targets, and predicting optimal treatments based on understanding the underlying molecular basis of the disease. Lastly, it reviews the preclinical models of restenosis and their application and limitation in the evaluation of device-based interventional technologies for the treatment of coronary artery diseases.